Clopidogrel Response in Acute Ischemic Stroke. The Bochumer CRISP Study

The aim of this study was to determine the prevalence rate and risk factors for chemical laboratory clopidogrel low-response (CLR) in the acute phase after an ischemic stroke.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Ischemic Stroke Brain Diseases Cardiovascular Diseases Central Nervous System Diseases Cerebrovascular Disorders Nervous System Diseases Stroke Vascular Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Department of Neurology, Ruhr University Bochum

Bochum, 44791, Germany

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

acute ischemic stroke
admittance to stroke unit
clopidogrel medication

Exclusion criteria

no consent
prior bleeding disorders
severe liver disorders
current gastrointestinal disorders
congestive heart failure
life-threatening malignancies

Treatment and study plan

Primary outcomes

Result of platelet function test

Time frame: one day

Aggregometry result of antiplatelet therapy

Interested in participating?

Completed

Looking for future studies?

Notify Me

Sponsors and collaborators

Lead sponsor

Ruhr University of Bochum

Other

Registry information

Official study title

Prevalence of Low Response to Clopidogrel in Patients After Acute Ischemic Stroke.

Acronym: Bo-CRISP

Important dates

Study start: 2010
Primary completion: 2012
Study completion: 2012
First posted: Apr 30, 2013
Registry last updated: Apr 30, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed